New antibody drug shows promise for tough eczema cases

NCT ID NCT06094179

Ongoing Disease control Sponsor: Bio-Thera Solutions Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new drug called BAT6026 in 33 adults with moderate to severe atopic dermatitis (eczema) that hasn't responded well to topical treatments. The drug is a monoclonal antibody given as an injection. The goal is to see if it is safe and can reduce eczema severity by at least 75% after 16 weeks. This early-phase trial will help determine the best dose for future studies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BAT6026 (a monoclonal antibody)
What this could lead to: If successful, this could point toward a new treatment option for people with moderate to severe atopic dermatitis that is not well controlled by current creams or ointments.
What could go wrong: This is an early-phase trial with only 33 participants, so results may not apply to everyone. The drug may not work better than placebo, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DERMATITIS ATOPIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DERMATITIS ATOPIC

Contacts and locations

Locations

Jianzhong Zhang

Beijing, Beijing Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.